Anti-LGI1 encephalitis

Neurology

Volumn 87, Issue 14, 2016, Pages 1449-1456

  Van Sonderen, Agnes ^a,b   Thijs, Roland D ^c   Coenders, Elias C ^a   Jiskoot, Lize C ^a   Sanchez, Esther ^d   De Bruijn, Marienke A A M ^a   Van Coevorden Hameete, Marleen H ^a,e   Wirtz, Paul W ^b   Schreurs, Marco W J ^a   Sillevis Smitt, Peter A E ^a   Titulaer, Maarten J ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

^b HAGA HOSPITAL   (Netherlands)

^c STICHTING EPILEPSIE INSTELLINGEN NEDERLAND SEIN   (Netherlands)

^d VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^e UTRECHT UNIVERSITY   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

LEUCINE RICH GLIOMA INACTIVATED 1 PROTEIN; PROTEIN; UNCLASSIFIED DRUG; AUTOANTIBODY; BIOLOGICAL MARKER; LGI1 PROTEIN, HUMAN;

ADULT; AGED; AMNESIA; ANTI LEUCINE RICH GLIOMA INACTIVATED 1 ENCEPHALITIS; ARTICLE; CASE FATALITY RATE; CLINICAL ARTICLE; CLINICAL FEATURE; COGNITION; COGNITIVE DEFECT; DAYTIME SOMNOLENCE; DISEASE COURSE; DISEASE SEVERITY; ENCEPHALITIS; EPWORTH SLEEPINESS SCALE; FEMALE; FOCAL EPILEPSY; FOLLOW UP; GLIOMA; HIPPOCAMPAL SCLEROSIS; HUMAN; IMMUNOHISTOCHEMISTRY; IMMUNOTHERAPY; LONG TERM CARE; MALE; MEDICAL RECORD; NETHERLANDS; NUCLEAR MAGNETIC RESONANCE IMAGING; PITTSBURGH SLEEP QUALITY INDEX; PRIORITY JOURNAL; PROSPECTIVE STUDY; RECURRENCE RISK; RETROSPECTIVE STUDY; TONIC CLONIC SEIZURE; TONIC SEIZURE; AUTOIMMUNE DISEASES; BLOOD; BRAIN; CEREBROSPINAL FLUID; DIAGNOSTIC IMAGING; IMMUNOLOGY; INCIDENCE; LIMBIC ENCEPHALITIS; MIDDLE AGED; PSYCHOLOGY; SYNDROME; TIME FACTOR; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; AUTOANTIBODIES; AUTOIMMUNE DISEASES; BIOMARKERS; BRAIN; FEMALE; FOLLOW-UP STUDIES; HUMANS; INCIDENCE; LIMBIC ENCEPHALITIS; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; PROTEINS; RETROSPECTIVE STUDIES; SYNDROME; TIME FACTORS;

EID: 84989944395     PISSN: 00283878     EISSN: 1526632X     Source Type: Journal    
DOI: 10.1212/WNL.0000000000003173     Document Type: Article

References (31)

1. Irani SR, Alexander S, Waters P, et al. Antibodies to Kv1 potassium channel-complex proteins leucine-rich, glioma inactivated 1 protein and contactin-associated protein-2 in limbic encephalitis, Morvan's syndrome and acquired neuromyotonia. Brain 2010;133:2734-2748.
2. Lai M, Huijbers MG, Lancaster E, et al. Investigation of LGI1 as the antigen in limbic encephalitis previously attributed to potassium channels: A case series. Lancet Neurol 2010;9:776-785.
3. Fukata Y, Lovero KL, Iwanaga T, et al. Disruption of LGI1-linked synaptic complex causes abnormal synaptic transmission and epilepsy. Proc Natl Acad Sci USA 2010;107:3799-3804.
4. Ohkawa T, Fukata Y, Yamasaki M, et al. Autoantibodies to epilepsy-related LGI1 in limbic encephalitis neutralize LGI1-ADAM22 interaction and reduce synaptic AMPA receptors. J Neurosci 2013;33:18161-18174.
5. Kalachikov S, Evgrafov O, Ross B, et al. Mutations in LGI1 cause autosomal-dominant partial epilepsy with auditory features. Nat Genet 2002;30:335-341.
6. Morante-Redolat JM, Gorostidi-Pagola A, Piquer-Sirerol S, et al. Mutations in the LGI1/Epitempin gene on 10q24 cause autosomal dominant lateral temporal epilepsy. Hum Mol Genet 2002;11:1119-1128.
7. Irani SR, Michell AW, Lang B, et al. Faciobrachial dystonic seizures precede Lgi1 antibody limbic encephalitis. Ann Neurol 2011;69:892-900.
8. Van Sonderen A, Schreurs MWJ, de Bruijn MA, et al. The relevance of VGKC positivity in the absence of LGI1 and Caspr2 antibodies. Neurology 2016;86:1692-1699.
9. Irani SR, Stagg CJ, Schott JM, et al. Faciobrachial dystonic seizures: The influence of immunotherapy on seizure control and prevention of cognitive impairment in a broadening phenotype. Brain 2013;136:3151-3162.
10. Graus F, Delattre JY, Antoine JC, et al. Recommended diagnostic criteria for paraneoplastic neurological syndromes. J Neurol Neurosurg Psychiatry 2004;75: 1135-1140.
11. Jansen C, Parchi P, Capellari S, et al. Human prion diseases in the Netherlands (1998-2009): clinical, genetic and molecular aspects. PLoS One 2012;7:e36333.
12. Titulaer MJ, Lang B, Verschuuren JJ. Lambert-Eaton myasthenic syndrome: from clinical characteristics to therapeutic strategies. Lancet Neurol 2011;10:1098-1107.
13. Shin YW, Lee ST, Shin JW, et al. VGKC-complex/LGI1-antibody encephalitis: clinical manifestations and response to immunotherapy. J Neuroimmunol 2013;265:75-81.
14. Irani SR, Gelfand JM, Bettcher BM, Singhal NS, Geschwind MD. Effect of rituximab in patients with leucine-rich, glioma-inactivated 1 antibody-associated encephalopathy. JAMA Neurol 2014;71:896-900.
15. Andrade DM, Tai P, Dalmau J, Wennberg R. Tonic seizures: A diagnostic clue of anti-LGI1 encephalitis Neurology 2011;76:1355-1357.
16. Rocamora R, Becerra JL, Fossas P, et al. Pilomotor seizures: An autonomic semiology of limbic encephalitis Seizure 2014;23:670-673.
17. Dalmau J, Gleichman AJ, Hughes EG, et al. Anti-NMDAreceptor encephalitis: case series and analysis of the effects of antibodies. Lancet Neurol 2008;7:1091-1098.
18. van Coevorden-Hameete MH, de GE, Titulaer MJ, Hoogenraad CC, Sillevis Smitt PA. Molecular and cellular mechanisms underlying anti-neuronal antibody mediated disorders of the central nervous system. Autoimmun Rev 2014;13:299-312.
19. Lau CG, Zukin RS. NMDA receptor trafficking in synaptic plasticity and neuropsychiatric disorders. Nat Rev Neurosci 2007;8:413-426.
20. Huganir RL, Nicoll RA. AMPARs and synaptic plasticity: The last 25 years. Neuron 2013;80:704-717.
21. Collingridge GL, Peineau S, Howland JG, Wang YT. Long-term depression in the CNS. Nat Rev Neurosci 2010;11:459-473.
22. Gabilondo I, Saiz A, Galan L, et al. Analysis of relapses in anti-NMDAR encephalitis. Neurology 2011;77:996-999.
23. Titulaer MJ, McCracken L, Gabilondo I, et al. Treatment and prognostic factors for long-term outcome in patients with anti-NMDA receptor encephalitis: An observational cohort study. Lancet Neurol 2013;12:157-165.
24. Hoftberger R, van Sonderen A, Leypoldt F, et al. Encephalitis and AMPA receptor antibodies: novel findings in a case series of 22 patients. Neurology 2015;84: 2403-2412.
25. Lai M, Hughes EG, Peng X, et al. AMPA receptor antibodies in limbic encephalitis alter synaptic receptor location. Ann Neurol 2009;65:424-434.
26. Malter MP, Frisch C, Schoene-Bake JC, et al. Outcome of limbic encephalitis with VGKC-complex antibodies: relation to antigenic specificity. J Neurol 2014;261: 1695-1705.
27. Kotsenas AL, Watson RE, Pittock SJ, et al. MRI findings in autoimmune voltage-gated potassium channel complex encephalitis with seizures: one potential etiology for mesial temporal sclerosis. AJNR Am J Neuroradiol 2014;35:84-89.
28. Malter MP, Helmstaedter C, Urbach H, Vincent A, Bien CG. Antibodies to glutamic acid decarboxylase define a form of limbic encephalitis. Ann Neurol 2010; 67:470-478.
29. Finke C, Kopp UA, Pajkert A, et al. Structural hippocampal damage following anti-N-methyl-D-aspartate receptor encephalitis. Biol Psychiatry 2015;79:727-734.
30. Gresa-Arribas N, Titulaer MJ, Torrents A, et al. Antibody titres at diagnosis and during follow-up of anti-NMDA receptor encephalitis: A retrospective study. Lancet Neurol 2014;13:167-177.
31. Hoftberger R, Titulaer MJ, Sabater L, et al. Encephalitis and GABAB receptor antibodies: novel findings in a new case series of 20 patients. Neurology 2013;81:1500-1506.